PMID- 30104900
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220318
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 10
DP  - 2018
TI  - Human leukocyte antigen gene polymorphisms are associated with systemic 
      inflammation in hepatitis B virus-related hepatocellular carcinoma.
PG  - 2315-2324
LID - 10.2147/CMAR.S167574 [doi]
AB  - BACKGROUND: Systemic inflammation (SI) is associated with tumor progression and 
      overall survival (OS) in patients with hepatocellular carcinoma (HCC). The 
      presence of some single nucleotide polymorphisms (SNPs) in the human leukocyte 
      antigen (HLA) region can influence the prognosis of patients with hepatitis B 
      virus (HBV)-related HCC, although the mechanism remains unknown. This study aimed 
      to analyze the correlations between HLA gene polymorphisms and SI. PATIENTS AND 
      METHODS: This study included 330 patients with HCC. The clinical parameters were 
      reviewed, and five SNPs, namely rs2647073, rs3997872, rs3077, rs7453920, and 
      rs7768538, were genotyped using the MassARRAY system. RESULTS: The rs3997872, 
      rs7453920, and rs7768538 genotypes were found to be significantly associated with 
      OS (P<0.05). The rs7453920 genotype was significantly associated with the 
      neutrophil/lymphocyte ratio (NLR; P=0.001), which was used as an SI index with a 
      threshold determined by receiver operating characteristic analysis. An elevated 
      NLR was also an independent predictor of OS according to univariate and 
      multivariate analyses (P<0.001). CONCLUSION: Our data show that HLA gene 
      polymorphisms are associated with SI in patients with HBV-related HCC, and the 
      absence of minor allele A (rs7453920) promotes SI and shortens OS.
FAU - Wu, Xiao-Long
AU  - Wu XL
AD  - Department of Hepatobiliary Surgery, caijianqiang@cicams.ac.cn.
FAU - Li, Zhi-Yu
AU  - Li ZY
AD  - Department of Hepatobiliary Surgery, caijianqiang@cicams.ac.cn.
FAU - Bi, Xin-Yu
AU  - Bi XY
AD  - Department of Hepatobiliary Surgery, caijianqiang@cicams.ac.cn.
FAU - Zhao, Hong
AU  - Zhao H
AD  - Department of Hepatobiliary Surgery, caijianqiang@cicams.ac.cn.
FAU - Zhao, Jian-Jun
AU  - Zhao JJ
AD  - Department of Hepatobiliary Surgery, caijianqiang@cicams.ac.cn.
FAU - Zhou, Jian-Guo
AU  - Zhou JG
AD  - Department of Hepatobiliary Surgery, caijianqiang@cicams.ac.cn.
FAU - Han, Yue
AU  - Han Y
AD  - Department of Interventional Therapies, National Cancer Center/Cancer Hospital, 
      Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 
      100021, China.
FAU - Huang, Zhen
AU  - Huang Z
AD  - Department of Hepatobiliary Surgery, caijianqiang@cicams.ac.cn.
FAU - Zhang, Ye-Fan
AU  - Zhang YF
AD  - Department of Hepatobiliary Surgery, caijianqiang@cicams.ac.cn.
FAU - Cai, Jian-Qiang
AU  - Cai JQ
AD  - Department of Hepatobiliary Surgery, caijianqiang@cicams.ac.cn.
LA  - eng
PT  - Journal Article
DEP - 20180731
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC6074760
OTO - NOTNLM
OT  - hepatitis B virus
OT  - hepatocellular carcinoma
OT  - human leukocyte antigen
OT  - single nucleotide polymorphism
OT  - systemic inflammation
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/08/15 06:00
MHDA- 2018/08/15 06:01
PMCR- 2018/07/31
CRDT- 2018/08/15 06:00
PHST- 2018/08/15 06:00 [entrez]
PHST- 2018/08/15 06:00 [pubmed]
PHST- 2018/08/15 06:01 [medline]
PHST- 2018/07/31 00:00 [pmc-release]
AID - cmar-10-2315 [pii]
AID - 10.2147/CMAR.S167574 [doi]
PST - epublish
SO  - Cancer Manag Res. 2018 Jul 31;10:2315-2324. doi: 10.2147/CMAR.S167574. 
      eCollection 2018.